Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Waterloo

$50,000.00

Development of tools for customizing and monitoring of acoustic treatment for COVID-19 patients_x000d_

EF 2020-21

Résumé
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented and award-winning pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally COVID-19. The company's Frequencer® device has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 650 devices in operations around the globe. Dymedso continues to explore the ways to improve its product to treat a wider range of patients requiring the airway. The goal of Dymedso (Richard Boudreault, CEO) and the University of Waterloo (Yuri Leonenko, PI) partnership is to customize of use of existent company devices for effective treatment of COVID-19 patients. Potential outcomes of the proposed research are the development of new tools (devices and protocols) which allow quantitatively: i) determine the optimal customized treatment for each particular patient; ii) real-time monitoring of the effectiveness of the acoustic treatment allowing adjustments if needed. It will dramatically increase the effectiveness and variety of treatment protocols depending on patient conditions, for example at the early phase of COVID-19, (the dry cough), or at the wet pneumonic phase of the disease.
Programme
Alliance Grants
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
554463-2020
Name nom
Leonenko, Yuri
Department département
Earth & Environmental Sciences
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of tools for customizing and monitoring of acoustic treatment for COVID-19 patients_x000d_
Keyword
NSERC
Application summary
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented and award-winning pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally COVID-19. The company's Frequencer® device has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 650 devices in operations around the globe. Dymedso continues to explore the ways to improve its product to treat a wider range of patients requiring the airway. The goal of Dymedso (Richard Boudreault, CEO) and the University of Waterloo (Yuri Leonenko, PI) partnership is to customize of use of existent company devices for effective treatment of COVID-19 patients. Potential outcomes of the proposed research are the development of new tools (devices and protocols) which allow quantitatively: i) determine the optimal customized treatment for each particular patient; ii) real-time monitoring of the effectiveness of the acoustic treatment allowing adjustments if needed. It will dramatically increase the effectiveness and variety of treatment protocols depending on patient conditions, for example at the early phase of COVID-19, (the dry cough), or at the wet pneumonic phase of the disease.